← SynDRA
CRIZOTINIB
SynDRA canonical compound SYN0020688 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | MET |
|---|
| Mechanism of action | ALK inhibitor |
|---|
| Indication | non-small cell lung cancer (NSCLC) |
|---|
| Disease area | oncology |
|---|
All known targets
- ALK
- MET
- ROS1
- MST1R
- NPM1
- AAK1
- PLK4
- NTRK1
- NTRK2
- NTRK3
- NUAK2
- PIP5K1A
Mechanisms of action (all sources)
- ALK INHIBITOR
- MET INHIBITOR
- Hepatocyte growth factor receptor inhibitor
- ALK tyrosine kinase receptor inhibitor
- ROS1 INHIBITOR
- Proto-oncogene tyrosine-protein kinase ROS inhibitor
- MST1R INHIBITOR
- Macrophage-stimulating protein receptor inhibitor
- EML4 INHIBITOR
- NPM1 INHIBITOR
- MET MODULATOR
- ROS1 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ADRA1A
- DLK1
- HTR2B
- PDE4D
- NPY1R
- HRH2
- KCNH2
- KDR
- ADRA2C
- ADORA3
- HTR2A
- SLC6A4
- PIK3CA
- NR1I2
- SLC6A3
- SLC6A2
- OPA1
- PAK4
- NQO2
- PASK
- PAK6
- NR3C1
- NUAK1
- PAK5
- PAK3
- OLA1
- OPRD1
- PAK2
- PAK1
- PAICS
- PCYT1A
- OXSR1
- OPRM1
- ABCB1
- PDGFRB
- PDE3A
- PDGFRA
- PIP4K2A
- PIM3
- PIM2
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CD74
- COMT
- SLC34A2
- SDC4
- PNMT
- NTMT1
- NTM1A
- NSD2
- NNMT
- KSYK
- IFNG
- IFNB1
- HNMT
- HLAB
- GNMT
- GAMT
- EML4
- CRBN
- CP3A7
- CP2D6
- CP2C9
- VHL
Drug classes
- Receptor Tyrosine Kinase Inhibitors
- Antineoplastic Agents
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Kinase Inhibitor
- Cytochrome P450 2B6 Inhibitors
- P-Glycoprotein Inhibitors
- Organic Cation Transporter 2 Inhibitors
- Cytochrome P450 3A Inhibitors
- Organic Cation Transporter 1 Inhibitors
- Tyrosine Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- XALKORI
- Xalkori
- xalkori
- PF-02341066
- Pf-2341066
- NSC-756645
- Xalkori (TN)
- novel ALK inhibitors
- PF 02341066
- (R)-crizotinib
- PF 2341066
- Crizotinib (PF-02341066)
- Crizotinib (PF-2341066)
- PF2341066
- CHEMBL601719
- CHEBI:64310
- 877399-52-5 (free base)
- 53AH36668S
- NSC 756645
- Crizotinib [USAN]
- Crizotinib [USAN:INN]
- crizotinibum
- UNII-53AH36668S
- VGH
- Crizotinib- Bio-X
- CRIZOTINIB [MI]
- CRIZOTINIB [INN]
- CRIZOTINIB [JAN]
- PF02341066
- CRIZOTINIB [VANDF]
- CRIZOTINIB [MART.]
- CRIZOTINIB [WHO-DD]
- SCHEMBL93829
- PF-2341066,Crizotinib
- Crizotinib (JAN/USAN/INN)
- GTPL4903
- CRIZOTINIB [ORANGE BOOK]
- Crizotinib, >=98% (HPLC)
Reported adverse events
- Abdominal discomfort
- Abdominal pain
- Abdominal tenderness
- Blood creatinine increased
- Bradycardia
- Chills
- Constipation
- Cough
- Diplopia
- Dizziness
- Dysgeusia
- Dyspepsia
Look up CRIZOTINIB in the interactive SynDRA portal →